PeerView Oncology
Targeting DNA Repair Defects Through PARPi in mPC: Why Are Somatic/Germline Alterations Important? How Can We Selectively Stop BRCA-Mutated Disease? Do BRCA 2 Carriers Have Worse Prognosis? What Are the Current NCCN Testing Guidelines?
By
PeerView Oncology
FEATURING
Emmanuel Antonarakis
By
PeerView Oncology
FEATURING
Emmanuel Antonarakis
Login to view comments.
Click here to Login